Faculty Sponsor

Jana Stedman

College

College of Nursing & Health Professions (CONHP)

Department/Program

Physician Assistant

Presentation Type

Poster Presentation

Symposium Date

Summer 7-24-2024

Abstract

Objective: Alzheimer’s disease presents a significant public health problem, characterized by a progressive loss of cognitive functioning ability, ultimately leading to severe dementia and loss of basic motor functions. With these patients accounting for a large percentage of hospital stays and healthcare expenditures, the urgency to address this disease is evident, particularly considering the projected growth of the aging population. This paper aims to explore new drug treatments that may alter the underlying process of Alzheimer’s disease and potentially prevent cognitive decline in future generations. Methods: Through a comprehensive review of studies examining monoclonal antibody drugs including aducanumab, lecanemab, and gantenerumab, their safety and efficacy was evaluated. To identify relevant studies, Google scholar was used with the following search terms” “Alzheimer’s disease”, “monoclonal antibody”, “aducanumab”, “lecanemab”, and “gantenerumab”. Results: While monoclonal antibody drugs have shown promise in reducing amyloid-beta plaques in the brain, their clinical significance in improving cognitive function remains unclear. Furthermore, limitations such as conflicting trial results, consideration of genotype-related factors, and need for long-term trials stress the complexity of treatment for Alzheimer’s disease. Conclusion: Future research should focus on confirming the underlying pathophysiology that causes cognitive impairment as well as exploring interventions beyond amyloid-beta reduction to address the multifaceted nature of Alzheimer’s disease.

Download

Share

COinS